(Q50899665)

25 March 2018

title

Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status. (English)

1 reference

25 March 2018

author

Louis Preston Garrison

1

object named as

Louis P Garrison

1 reference

25 March 2018

Joseph B Babigumira

4

object named as

Joseph B Babigumira

1 reference

25 March 2018

Edith A. Perez

6

object named as

Edith A Perez

1 reference

25 March 2018

author name string

Deepa Lalla

2

1 reference

25 March 2018

Melissa Brammer

3

1 reference

25 March 2018

Bruce Wang

5

1 reference

25 March 2018

language of work or name

English

0 references

publication date

17 June 2013

1 reference

25 March 2018

published in

Cancer

1 reference

25 March 2018

volume

119

1 reference

25 March 2018

issue

17

1 reference

25 March 2018

page(s)

3113-3122

1 reference

25 March 2018

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

HER2-positive breast cancer: current treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

Systematic review of HER2 breast cancer testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

Handling uncertainty in cost-effectiveness models

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

Does Medicare have an implicit cost-effectiveness threshold?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

The cost-effectiveness of primary stroke centers for acute stroke care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

Saving lives with accurate HER2 testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

The cardiac safety of trastuzumab in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

HER2 status and benefit from adjuvant trastuzumab in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

inferred from DOI database lookup

7 January 2021

based on heuristic

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28196

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.28196

1 reference

25 March 2018

1 reference

25 March 2018